Recombinant AP Anti-Fibrinogen alpha chain antibody [EPR2919] (ab308667)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Alkaline Phosphatase Rabbit monoclonal [EPR2919] to Fibrinogen Alpha Chain
- Suitable for: Target binding affinity, Antibody labelling
- Conjugation: Alkaline Phosphatase
Related conjugates and formulations
Overview
-
Product name
AP Anti-Fibrinogen alpha chain antibody [EPR2919]
See all Fibrinogen Alpha Chain primary antibodies -
Description
Alkaline Phosphatase Rabbit monoclonal [EPR2919] to Fibrinogen Alpha Chain -
Host species
Rabbit -
Conjugation
Alkaline Phosphatase -
Tested applications
Suitable for: Target binding affinity, Antibody labellingmore details -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
General notes
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for Abtrial: learn more here.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.1% Proclin 300 Solution
Constituents: 50% Glycerol (glycerin, glycerine), 1% BSA, 0.016% Magnesium chloride, 0.001% Zinc chloride -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR2919 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
- PE Anti-Fibrinogen alpha chain antibody [EPR2919] (ab303122)
- APC Anti-Fibrinogen alpha chain antibody [EPR2919] (ab303123)
- HRP Anti-Fibrinogen alpha chain antibody [EPR2919] (ab303124)
- Alexa Fluor® 488 Anti-Fibrinogen alpha chain antibody [EPR2919] (ab309639)
- Alexa Fluor® 647 Anti-Fibrinogen alpha chain antibody [EPR2919] (ab310005)
- Alexa Fluor® 555 Anti-Fibrinogen alpha chain antibody [EPR2919] (ab311893)
- Alexa Fluor® 568 Anti-Fibrinogen alpha chain antibody [EPR2919] (ab312364)
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab308667 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Target binding affinity |
Use at an assay dependent concentration.
|
|
Antibody labelling |
Use at an assay dependent concentration.
|
Notes |
---|
Target binding affinity
Use at an assay dependent concentration. |
Antibody labelling
Use at an assay dependent concentration. |
Target
-
Function
Fibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation. -
Tissue specificity
Plasma. -
Involvement in disease
Defects in FGA are a cause of congenital afibrinogenemia (CAFBN) [MIM:202400]. This is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Note=The majority of cases of afibrinogenemia are due to truncating mutations. Variations in position Arg-35 (the site of cleavage of fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.
Defects in FGA are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash. -
Sequence similarities
Contains 1 fibrinogen C-terminal domain. -
Domain
A long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure. -
Post-translational
modificationsThe alpha chain is not glycosylated.
Forms F13A-mediated cross-links between a glutamine and the epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen heteropolymers.
About one-third of the alpha chains in the molecules in blood were found to be phosphorylated.
Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
Phosphorylation sites are present in the extracelllular medium. -
Cellular localization
Secreted. - Information by UniProt
-
Alternative names
- Ac1873 antibody
- Fba5e antibody
- FGA antibody
see all
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab308667 has not yet been referenced specifically in any publications.